Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

IlMytConi

ABSTRACT: Mythimna conigera (brown-line bright-eye)

PROVIDER: PRJEB82381 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	ERR13947551_1.fastq.gz	Fastqsanger.gz
	ERR13947551_2.fastq.gz	Fastqsanger.gz
	ERR13957077.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

ilMytConi

Project description:Mythimna conigera (brown-line bright-eye), genomic and transcriptomic data

| PRJEB82380 | ENA

ilLacOler

Project description:Lacanobia oleracea (bright-line brown-eye)

| PRJEB61355 | ENA

ilLacOler1

Project description:Lacanobia oleracea (bright-line brown-eye) genome assembly, ilLacOler1

| PRJEB61762 | ENA

ilLacOler

Project description:Lacanobia oleracea (bright-line brown-eye), genomic and transcriptomic data

| PRJEB61354 | ENA

ilLacOler1 alternate haplotype

Project description:Lacanobia oleracea (bright-line brown-eye) genome assembly, ilLacOler1, alternate haplotype

| PRJEB61763 | ENA

Loss of Bright/Arid3A reprograms MEFs to a pluripotent state

Project description:Bright null mouse embryonic stem cells and spontaneously reprogrammed Bright null cells compared to WT mouse embryonic stem cells;Work further described in Popowski et. al 2013 Bright null mouse embryonic stem cells and wildtype mouse embryonic stem cells differentiated in embryoid bodies at day 6 and day 15 Total RNA from each cell line using indicated replicates

2013-11-25 | E-GEOD-52692 | biostudies-arrayexpress

Catharanthus roseus strain:ASab-1 | cultivar:little bright eye

Project description:Catharanthus roseus strain:ASab-1 | cultivar:little bright eye Raw sequence reads

| PRJNA289707 | ENA

Project description:Hy-Line Brown hens

| PRJNA1095718 | ENA

Establishment of biomarkers to predict response to glucocorticoids for thyroid eye disease by DIA proteome analysis.

Project description:The standard treatment for thyroid eye disease is glucocorticoid administration, however its response varies from case to case. In recent years, treatment of thyroid eye disease has evolved dramatically, and the efficacy of several agents is being demonstrated. If steroid resistance is identified prior to treatment, the quality of care can be improved by using other agents as first-line therapy. We performed DIA proteome analysis on pretreatment sera of glucocorticoids response and resistance patients to search for candidate biomarkers of therapeutic response. Sera from healthy subjects and those with Graves' disease without thyroid eye disease are also analyzed together as controls.

2026-03-12 | PXD061741 | JPOST Repository

Loss of Bright/Arid3A reprograms MEFs to a pluripotent state

2013-11-25 | GSE52692 | GEO